{"id":"novolog-novorapid","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypoglycemia"},{"rate":"5-10%","effect":"Injection site reactions"},{"rate":"5-10%","effect":"Weight gain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by stimulating glucose uptake in cells, inhibiting glucose production in the liver, and promoting the storage of glucose in muscles and fat cells. This results in a decrease in blood glucose levels. NovoLog/NovoRapid is administered via subcutaneous injection and has a rapid onset of action, making it suitable for mealtime glucose control.","oneSentence":"NovoLog/NovoRapid is a rapid-acting insulin analog that mimics the action of natural insulin to lower blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:33.012Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes"},{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT02556840","phase":"NA","title":"Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-04-25","conditions":"Maturity-Onset Diabetes of the Young","enrollment":46},{"nctId":"NCT06948760","phase":"NA","title":"Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D","status":"COMPLETED","sponsor":"Mark D. DeBoer, MD, MSc., MCR","startDate":"2025-07-23","conditions":"Type 1 Diabetes","enrollment":11},{"nctId":"NCT04542148","phase":"PHASE2","title":"Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2022-02-10","conditions":"Diabetes Mellitus, Type 2, Preterm Birth, Pregnancy, High Risk","enrollment":120},{"nctId":"NCT04149262","phase":"","title":"Fiasp® Versus NovoRapid® in Children With Type 1 Diabetes on MiniMed 640G Pump With Sensor","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2019-11-15","conditions":"Type 1 Diabetes","enrollment":44},{"nctId":"NCT05799781","phase":"NA","title":"Two Way Crossover Closed Loop MPC vs Control IQ","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2023-03-13","conditions":"Type 1 Diabetes","enrollment":29},{"nctId":"NCT05539872","phase":"PHASE2, PHASE3","title":"Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers","status":"COMPLETED","sponsor":"Amphastar Pharmaceuticals, Inc.","startDate":"2022-08-22","conditions":"Pharmacokinetics, Pharmacodynamics","enrollment":69},{"nctId":"NCT04416269","phase":"PHASE4","title":"Oral Anti Diabetic Agents in the Hospital","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-08-07","conditions":"Diabetes Mellitus","enrollment":255},{"nctId":"NCT07173712","phase":"PHASE4","title":"Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Yanbing Li","startDate":"2026-03-15","conditions":"Type 2 Diabetes","enrollment":324},{"nctId":"NCT07387003","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2026-03-20","conditions":"Type 2 Diabetes (T2DM)","enrollment":300},{"nctId":"NCT06492226","phase":"PHASE1","title":"Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(A), US-NovoLog®, and EU-NovoRapid®","status":"COMPLETED","sponsor":"Xentria, Inc.","startDate":"2024-07-30","conditions":"Healthy Participants","enrollment":54},{"nctId":"NCT07076199","phase":"PHASE3","title":"A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-08-11","conditions":"Diabetes Mellitus, Type 1","enrollment":877},{"nctId":"NCT06445946","phase":"PHASE4","title":"DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2024-08-01","conditions":"Gestational Diabetes Mellitus, Pregnancy, High Risk","enrollment":1572},{"nctId":"NCT05069545","phase":"","title":"A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-10-11","conditions":"Diabetes Mellitus, Type 1","enrollment":411},{"nctId":"NCT06547619","phase":"EARLY_PHASE1","title":"Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM","status":"RECRUITING","sponsor":"Anna Stanhewicz, PhD","startDate":"2024-10-01","conditions":"Gestational Diabetes, Endothelial Dysfunction, Physical Inactivity","enrollment":40},{"nctId":"NCT04848480","phase":"PHASE3","title":"A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-04-30","conditions":"Diabetes Mellitus, Type 1","enrollment":582},{"nctId":"NCT04698018","phase":"PHASE1","title":"A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-04-20","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":23},{"nctId":"NCT04880850","phase":"PHASE3","title":"A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-05-14","conditions":"Diabetes Mellitus, Type 2","enrollment":582},{"nctId":"NCT04588259","phase":"PHASE3","title":"Research Study to Compare a New Medicine \"Fast-acting Insulin Aspart\" to Another Medicine \"Insulin Aspart\" in Chinese People With Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-10-09","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":331},{"nctId":"NCT05417841","phase":"NA","title":"Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM","status":"COMPLETED","sponsor":"Beijing Hospital","startDate":"2023-03-23","conditions":"Type 2 Diabetes Mellitus","enrollment":218},{"nctId":"NCT02546401","phase":"PHASE3","title":"Comparison of Insulin's Injection Before or After the Meal in Type 1 Diabetic Patients Treated With Insulin Pump","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2015-09","conditions":"Diabetes Type 1","enrollment":22},{"nctId":"NCT05013229","phase":"PHASE3","title":"A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-11-30","conditions":"Diabetes Mellitus, Type 2","enrollment":679},{"nctId":"NCT06767761","phase":"PHASE3","title":"A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Type 2 Diabetes Mellitus Subjects (T2DM) Treated With Basal + Prandial Insulin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-02-18","conditions":"Diabetes","enrollment":580},{"nctId":"NCT04124302","phase":"PHASE4","title":"The Impact of Two Different Insulin Dose Calculation on Postprandial Glycemia After Mixed Meal.","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2019-10-01","conditions":"Diabetes Mellitus, Type 1","enrollment":76},{"nctId":"NCT05413369","phase":"PHASE3","title":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-07-07","conditions":"Type 2 Diabetes Mellitus","enrollment":582},{"nctId":"NCT07068295","phase":"PHASE1","title":"A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 2 Diabetes When Given by an Insulin Pump","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-07-11","conditions":"Diabetes Mellitus, Type 2","enrollment":65},{"nctId":"NCT06809621","phase":"PHASE1","title":"A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 1 Diabetes When Given by an Insulin Pump","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2025-01-29","conditions":"Diabetes Mellitus, Type 1","enrollment":43},{"nctId":"NCT02054429","phase":"PHASE1","title":"Intensive Insulin Therapy With Tight Glycemic Control to Improve Outcomes After Endovascular Therapy for Acute Ischemic Stroke","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2013-01","conditions":"Ischemic Stroke","enrollment":30},{"nctId":"NCT02462161","phase":"PHASE1","title":"Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2015-03-20","conditions":"Alzheimer's Disease, Mild Cognitive Impairment","enrollment":24},{"nctId":"NCT02879409","phase":"NA","title":"HbA1c Variability in Type II Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Cornell Medical College in Qatar","startDate":"2016-11","conditions":"Diabetes Mellitus Type 2","enrollment":150},{"nctId":"NCT05224258","phase":"NA","title":"Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp®","status":"COMPLETED","sponsor":"Medtronic Diabetes","startDate":"2022-03-17","conditions":"Type 1 Diabetes","enrollment":240},{"nctId":"NCT05946785","phase":"EARLY_PHASE1","title":"Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes","status":"RECRUITING","sponsor":"Anna Stanhewicz, PhD","startDate":"2023-07-01","conditions":"Gestational Diabetes, Vascular Endothelial Function","enrollment":28},{"nctId":"NCT05946798","phase":"EARLY_PHASE1","title":"Role of NADPH Oxidase in Microvascular Dysfunction Following GDM","status":"RECRUITING","sponsor":"Anna Stanhewicz, PhD","startDate":"2023-08-30","conditions":"Gestational Diabetes, Oxidative Stress, Vascular Endothelial Function","enrollment":40},{"nctId":"NCT04974528","phase":"PHASE3","title":"Afrezza® INHALE-1 Study in Pediatrics","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2021-09-29","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":319},{"nctId":"NCT03987308","phase":"NA","title":"Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients","status":"RECRUITING","sponsor":"Beijing Hospital","startDate":"2019-07-02","conditions":"Type 2 Diabetic Patients, T2DM (Type 2 Diabetes Mellitus), T2DM","enrollment":115},{"nctId":"NCT02496780","phase":"PHASE2, PHASE3","title":"The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2015-08","conditions":"Cystic Fibrosis","enrollment":65},{"nctId":"NCT04381429","phase":"PHASE4","title":"Effect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related Diabetes","status":"TERMINATED","sponsor":"University Hospital, Strasbourg, France","startDate":"2020-08-17","conditions":"Cystic Fibrosis-related Diabetes","enrollment":38},{"nctId":"NCT04200313","phase":"NA","title":"The Insulin-Only Bionic Pancreas Pivotal Trial","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2020-03-31","conditions":"Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Type 1","enrollment":440},{"nctId":"NCT04538352","phase":"PHASE4","title":"Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2021-01-18","conditions":"Type 2 Diabetes","enrollment":60},{"nctId":"NCT06199505","phase":"PHASE2","title":"A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2023-11-21","conditions":"Type 2 Diabetes","enrollment":153},{"nctId":"NCT06739473","phase":"PHASE4","title":"Total-body Glucose Utilization in Obesity","status":"RECRUITING","sponsor":"Turku University Hospital","startDate":"2023-01-25","conditions":"Obesity and Overweight","enrollment":60},{"nctId":"NCT05653050","phase":"NA","title":"Closing the Loop in People with Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Cambridge","startDate":"2023-02-20","conditions":"Type 1 Diabetes","enrollment":26},{"nctId":"NCT05218915","phase":"PHASE4","title":"Basal Plus GLP1-ra on Glycemic Variability in CKD","status":"COMPLETED","sponsor":"Elaine Chow","startDate":"2022-01-28","conditions":"Diabetes Mellitus, Diabetic Kidney Disease","enrollment":95},{"nctId":"NCT03987802","phase":"","title":"An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-01-20","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":42},{"nctId":"NCT06607224","phase":"NA","title":"Effect of the Use of Continuous Glucose Monitoring Versus Standard Glycemic Control in Hospitalized Patients with Type 2 Diabetes.","status":"COMPLETED","sponsor":"Hospital General Universitario Gregorio Marañon","startDate":"2022-01-10","conditions":"Diabetes Mellitus Type 2, Hospitalization","enrollment":40},{"nctId":"NCT04042441","phase":"","title":"A Research Study, Looking at How Ryzodeg® (Insulin Degludec/Insulin Aspart) Works in People With Type 2 Diabetes in Local Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-07-29","conditions":"Diabetes Mellitus, Type 2","enrollment":1122},{"nctId":"NCT06558708","phase":"PHASE2","title":"A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection OD","status":"RECRUITING","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2024-06-28","conditions":"Type 2 Diabetes","enrollment":60},{"nctId":"NCT06532461","phase":"NA","title":"A Trial of Three- and Seven-days Insulin Infusions Set","status":"RECRUITING","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2024-07-20","conditions":"Type 1 Diabetes","enrollment":80},{"nctId":"NCT05221580","phase":"","title":"China Research of IDEgAsp Treatment in Real-world Clinical practicE (CREATE)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-03-18","conditions":"Diabetes Mellitus, Type 2","enrollment":887},{"nctId":"NCT06375031","phase":"PHASE1","title":"Comparison of HR011408 and NovoRapid® in Subjects With Diabetics","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-05","conditions":"Diabetes","enrollment":30},{"nctId":"NCT02871089","phase":"NA","title":"Closed Loop From Onset in Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cambridge","startDate":"2017-01","conditions":"Diabetes Mellitus, Type 1 Diabetes","enrollment":96},{"nctId":"NCT05284344","phase":"","title":"The Impact of Glucotoxicity on Gastric Emptying in Chinese Patients With Newly Diagnosed Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Adelaide","startDate":"2021-01-24","conditions":"Type 2 Diabetes","enrollment":78},{"nctId":"NCT04012138","phase":"PHASE4","title":"Insulin Dextrose Infusion vs Nebulized Salbutamol vs Combination of Salbutamol and Insulin Dextrose in Acute Hyperkalemia","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2019-12-20","conditions":"Hyperkalemia","enrollment":525},{"nctId":"NCT03874715","phase":"PHASE3","title":"Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-03-11","conditions":"Type 1 Diabetes Mellitus","enrollment":210},{"nctId":"NCT04460326","phase":"PHASE3","title":"Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2020-12-07","conditions":"Type 2 Diabetes Treated With Insulin","enrollment":137},{"nctId":"NCT03700801","phase":"PHASE4","title":"Study of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic Therapy","status":"COMPLETED","sponsor":"Zhujiang Hospital","startDate":"2018-10-01","conditions":"Type 2 Diabetes Mellitus","enrollment":130},{"nctId":"NCT05754424","phase":"PHASE1","title":"AT278, NovoRapid® and Humulin® R (U500) in Glucose Clamp Study","status":"COMPLETED","sponsor":"Arecor Limited","startDate":"2023-02-27","conditions":"Diabetes Mellitus, Type 2","enrollment":41},{"nctId":"NCT05737576","phase":"PHASE1","title":"The Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid® in Healthy Subject","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-03-20","conditions":"Diabetes","enrollment":61},{"nctId":"NCT02518945","phase":"PHASE3","title":"Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2015-08","conditions":"Type 1 Diabetes Mellitus","enrollment":26},{"nctId":"NCT00671008","phase":"","title":"Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-12","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":400},{"nctId":"NCT00447382","phase":"PHASE3","title":"Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-03","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":330},{"nctId":"NCT01524705","phase":"PHASE4","title":"FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)","status":"COMPLETED","sponsor":"University of Washington","startDate":"2012-08","conditions":"Type 2 Diabetes","enrollment":102},{"nctId":"NCT02491528","phase":"PHASE3","title":"A Phase III Study of Insulin Aspart Injection to Evaluate the Efficacy and Safety","status":"COMPLETED","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2015-06-19","conditions":"Diabetes","enrollment":563},{"nctId":"NCT05360537","phase":"PHASE4","title":"Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2021-04-01","conditions":"Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT03660553","phase":"PHASE4","title":"Simplified Insulin Regimen for the Elderly","status":"TERMINATED","sponsor":"University of Miami","startDate":"2018-10-10","conditions":"Type 2 Diabetes Mellitus","enrollment":7},{"nctId":"NCT04019821","phase":"PHASE4","title":"Super-Bolus: Effects on Postprandial Glycemia After High Glycemic Index Meal","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2020-01-01","conditions":"Diabetes Mellitus, Type 1","enrollment":72},{"nctId":"NCT06127433","phase":"PHASE4","title":"The Effect of Short-term Insulin Intensive Therapy Based on the Application of Insulin Pump and Real-time Dynamic Glucose Monitoring Technology on Reversing the Newly Diagnosed Type 2 Diabetes","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2023-03-07","conditions":"Insulin Pump，Continuous Glucose Monitoring Technology","enrollment":210},{"nctId":"NCT00504673","phase":"PHASE3","title":"Comparison of Insulin Detemir Versus Insulin NPH on Weight Change in Overweight and Obese With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":277},{"nctId":"NCT00101751","phase":"PHASE4","title":"INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":4877},{"nctId":"NCT00267683","phase":"PHASE3","title":"Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2005-12","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":9},{"nctId":"NCT00849316","phase":"","title":"Safety and Efficacy Study of NovoRapid™ in Patients With Coexisting Diabetes and Kidney Disease","status":"WITHDRAWN","sponsor":"Novo Nordisk A/S","startDate":"2009-02","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT01486862","phase":"PHASE4","title":"Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":26},{"nctId":"NCT00476437","phase":"PHASE3","title":"Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":81},{"nctId":"NCT05199714","phase":"NA","title":"A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2022-02-21","conditions":"Type 1 Diabetes","enrollment":12},{"nctId":"NCT05262595","phase":"PHASE1","title":"A Study to Look at How Insulin NNC0471-0119 Works in the Body in People With Type 1 Diabetes When Injected by Insulin Pump","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-03-03","conditions":"Diabetes Mellitus, Type 1","enrollment":19},{"nctId":"NCT02408120","phase":"PHASE4","title":"Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-10","conditions":"Diabetes Mellitus, Type 2","enrollment":226},{"nctId":"NCT00913497","phase":"PHASE4","title":"The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children","status":"COMPLETED","sponsor":"Corewell Health West","startDate":"2009-06","conditions":"Type 1 Diabetes Mellitus","enrollment":16},{"nctId":"NCT03737240","phase":"PHASE3","title":"IDegLira HIGH Trial","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-01-15","conditions":"Diabetes Mellitus","enrollment":145},{"nctId":"NCT03659799","phase":"PHASE4","title":"Comparison of FiAsp and Aspart During Postprandial Exercise in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2019-04-12","conditions":"Type 1 Diabetes Mellitus","enrollment":40},{"nctId":"NCT03666065","phase":"EARLY_PHASE1","title":"Diluted Insulin in Young Children: Bigger Volumes for Smaller Patients","status":"COMPLETED","sponsor":"Yale University","startDate":"2020-01-01","conditions":"Type1diabetes","enrollment":3},{"nctId":"NCT05726461","phase":"NA","title":"Efficacy and Safety of Android Artificial Pancreas System in Adult Patients With Type 1 Diabetes Mellitus in China","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2023-02-11","conditions":"Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders","enrollment":25},{"nctId":"NCT02036372","phase":"NA","title":"Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2014-01","conditions":"Diabetes Mellitus Type II","enrollment":150},{"nctId":"NCT00788840","phase":"PHASE4","title":"Detemir Energy Expenditure Study","status":"COMPLETED","sponsor":"University of Surrey","startDate":"2008-01","conditions":"Type 2 Diabetes Mellitus, Obesity","enrollment":30},{"nctId":"NCT03770767","phase":"PHASE3","title":"Insulin Fiasp vs. Insulin Novorapid During Pregnancy and Laction in Women With Pre-existing Diabetes","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2019-11-11","conditions":"Diabetes Mellitus, Pregnancy Complications","enrollment":216},{"nctId":"NCT01333514","phase":"PHASE4","title":"Carbohydrate Consumption as a Factor in Aspart Dosing","status":"TERMINATED","sponsor":"Rush University Medical Center","startDate":"2011-04","conditions":"Diabetes","enrollment":14},{"nctId":"NCT02621489","phase":"PHASE4","title":"Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2015-12","conditions":"Atherosclerosis, Diabetes, Restenosis","enrollment":38},{"nctId":"NCT05802862","phase":"PHASE3","title":"A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China","status":"UNKNOWN","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2023-05-01","conditions":"Diabetes","enrollment":408},{"nctId":"NCT03387787","phase":"PHASE2, PHASE3","title":"Evaluation of Glycaemic Control Using GlucoTab® With Insulin Degludec in Hospitalized Patients With Diabetes Mellitus Type 2","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2018-01-30","conditions":"Type 2 Diabetes Mellitus","enrollment":15},{"nctId":"NCT04243629","phase":"NA","title":"Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System in Adults With Type 1 Diabetes","status":"UNKNOWN","sponsor":"McGill University","startDate":"2021-11-12","conditions":"Diabetes Mellitus, Type 1, Type 1 Diabetes, Postprandial Hyperglycemia","enrollment":26},{"nctId":"NCT05767255","phase":"PHASE3","title":"Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue","status":"UNKNOWN","sponsor":"Hospital Universitario San Ignacio","startDate":"2022-12-01","conditions":"Diabetes Mellitus, Type 2 Treated With Insulin","enrollment":66},{"nctId":"NCT04759144","phase":"NA","title":"FASter Insulin in Closed-loop Technology in Children","status":"COMPLETED","sponsor":"University of Cambridge","startDate":"2021-03-12","conditions":"Type 1 Diabetes Mellitus","enrollment":27},{"nctId":"NCT05719961","phase":"PHASE1","title":"Bioequivalence Study of INS062 and Pharmacokinetics and Pharmacokinetics Study of Single Injection of HR20014 in Healthy Subjects","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-01-05","conditions":"Diabetes","enrollment":60},{"nctId":"NCT03377699","phase":"PHASE3","title":"Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-11-22","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":225},{"nctId":"NCT04655690","phase":"PHASE1","title":"A Study to Look at How Safe Insulin NNC0471-0119 is and How it Works in People With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-11-09","conditions":"Diabetes Mellitus, Type 1","enrollment":48},{"nctId":"NCT03262116","phase":"PHASE2, PHASE3","title":"Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2019-03-19","conditions":"Type 1 Diabetes Mellitus","enrollment":20},{"nctId":"NCT05641337","phase":"PHASE3","title":"Research on Optimal Strategy of Hypoglycemic Therapy for Cirrhosis With Diabetes","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2022-10-01","conditions":"Liver Cirrhosis, Diabetes","enrollment":184},{"nctId":"NCT03689374","phase":"PHASE3","title":"A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-10-01","conditions":"Diabetes Mellitus, Type 2","enrollment":2274},{"nctId":"NCT04892069","phase":"","title":"Investigating the Effect of Ryzodeg® in Adult Patients With Type 2 Diabetes in Lebanon","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-05-27","conditions":"Diabetes Mellitus, Type 2","enrollment":60},{"nctId":"NCT01053234","phase":"NA","title":"Different Insulin Regimens and Postprandial Coagulation Activation","status":"COMPLETED","sponsor":"Esbjerg Hospital - University Hospital of Southern Denmark","startDate":"2007-02","conditions":"Type 2 Diabetes, Cardiovascular Risk, Hemostasis","enrollment":78},{"nctId":"NCT04163874","phase":"NA","title":"Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas","status":"COMPLETED","sponsor":"McGill University","startDate":"2020-02-14","conditions":"Type 1 Diabetes, Type 1 Diabetes Mellitus, Hyperglycemia, Postprandial","enrollment":36},{"nctId":"NCT05184868","phase":"PHASE1","title":"AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study","status":"COMPLETED","sponsor":"Arecor Limited","startDate":"2022-01-03","conditions":"Diabetes Mellitus, Type 1","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Insulin aspart"],"phase":"phase_3","status":"active","brandName":"NovoLog/NovoRapid","genericName":"NovoLog/NovoRapid","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NovoLog/NovoRapid is a rapid-acting insulin analog that mimics the action of natural insulin to lower blood glucose levels. Used for Type 1 diabetes, Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}